An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification

Stat3/Socs3 Activation by IL-6 Transsignaling Promotes Progression of Pancreatic Intraepithelial Neoplasia and Development of Pancreatic Cancer

(2011) Marina Lesina et al.   CANCER CELL

Species Specificity of ADAM10 and ADAM17 Proteins in Interleukin-6 (IL-6) Trans-signaling and Novel Role of ADAM10 in Inducible IL-6 Receptor Shedding

(2011) Christoph Garbers et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

An Emerging 1q21.1 Deletion-Associated Neurodevelopmental Phenotype

(2011) Lina Basel-Vanagaite et al.   JOURNAL OF CHILD NEUROLOGY

The molecular characterization and clinical management of multiple myeloma in the post-genome era

(2009) Y Zhou et al.   LEUKEMIA

Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma

(2009) I. Aladzsity et al.   LEUKEMIA RESEARCH

Recurrent reciprocal 1q21.1 deletions and duplications associated with microcephaly or macrocephaly and developmental and behavioral abnormalities

(2008) Nicola Brunetti-Pierri et al.   NATURE GENETICS